AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31288354 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% povidone-iodine for 1.0 minute
Number of subjects: 400
Study 31288354 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% povidone-iodine for 2.0 minutes
Number of subjects: 400
Study 31288354 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% povidone-iodine for 3.5 minutes
Number of subjects: 400
Study 31288354 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 400
Study 26715522 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-treated group (50 mg elemental iron/daily)
Number of subjects: 70
Study 26715522 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 70
Study 25168031 — intervention group
Group type: EXPERIMENTAL
Intervention: E‐cigarette use
Number of subjects: 4660
Study 24712716 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg/day)
Number of subjects: 60
Study 24712716 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg/day)
Number of subjects: 60
Study 24712716 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50 mg/day)
Number of subjects: 60
Study 24712716 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 60
Study 17822748 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-ifosfamide and mesna (CIM)
Number of subjects: 206
Study 17822748 — intervention group
Group type: COMPARATOR
Intervention: Whole abdominal irradiation (WAI)
Number of subjects: 206
Study 15195691 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine solution (20 mg)
Number of subjects: 24
Study 15195691 — intervention group
Group type: COMPARATOR
Intervention: Nicardipine tablets (20 mg)
Number of subjects: 24
Study 11214632 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparinized EVD catheters
Number of subjects: 198
Study 11214632 — intervention group
Group type: COMPARATOR
Intervention: Unheparinized EVD catheters
Number of subjects: 198
Study 11214632 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparinized EVD catheters in patients with subarachnoid hemorrhages
Number of subjects: 198
Study 11214632 — intervention group
Group type: COMPARATOR
Intervention: Unheparinized EVD catheters in patients with subarachnoid hemorrhages
Number of subjects: 198
Study 9433410 — intervention group
Group type: EXPERIMENTAL
Intervention: Ileocolonoscopy and biopsy
Number of subjects: 24
Study 8366184 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (80 mg daily)
Number of subjects: 15
Study 8366184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 2871952 — intervention group
Group type: EXPERIMENTAL
Intervention: GRF 1-29 (100 or 50 micrograms as i.v. bolus)
Number of subjects: 0
Study 2871952 — intervention group
Group type: COMPARATOR
Intervention: Atropine (1.2 mg, i.v.)
Number of subjects: 0
Study 2871952 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide (MCP, 10 mg, i.v.)
Number of subjects: 0
Study 2871952 — intervention group
Group type: COMPARATOR
Intervention: Thymoxamine (THYM, 210 micrograms/min, 150 min infusion)
Number of subjects: 0
Study 2871952 — intervention group
Group type: COMPARATOR
Intervention: TRH administration
Number of subjects: 0
Study 31127363 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention including continuing medical education, distribution of guidelines, and educational outreach visits in Berlin (intervention region)
Number of subjects: 1900
Study 31127363 — intervention group
Group type: COMPARATOR
Intervention: No specific interventions in Hamburg (control region)
Number of subjects: 1900
Study 28986719 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D imaging system
Number of subjects: 0
Study 28986719 — intervention group
Group type: COMPARATOR
Intervention: 2D imaging system
Number of subjects: 0
Study 25601942 — intervention group
Group type: EXPERIMENTAL
Intervention: JENVAC (2 doses, 28 days apart)
Number of subjects: 0
Study 25601942 — intervention group
Group type: COMPARATOR
Intervention: SA-14-14-2 (single dose)
Number of subjects: 0
Study 25601942 — intervention group
Group type: EXPERIMENTAL
Intervention: JENVAC (single dose)
Number of subjects: 0
Study 25601942 — intervention group
Group type: EXPERIMENTAL
Intervention: JENVAC (2 doses)
Number of subjects: 0
Study 25601942 — intervention group
Group type: EXPERIMENTAL
Intervention: JENVAC
Number of subjects: 0
Study 25601942 — intervention group
Group type: EXPERIMENTAL
Intervention: JENVAC and SA-14-14-2
Number of subjects: 0
Study 24664356 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded Response Model (GRM)
Number of subjects: 1296
Study 23131813 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea (1.0 g sachets, 3 cups per day for 60 days)
Number of subjects: 45
Study 23131813 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 45
Study 19526157 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol infusion (0.5 gm/kg) during ESWL
Number of subjects: 38
Study 19526157 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 38
Study 17333451 — intervention group
Group type: EXPERIMENTAL
Intervention: PTH(1‐84)
Number of subjects: 119
Study 17333451 — intervention group
Group type: COMPARATOR
Intervention: Alendronate
Number of subjects: 119
Study 15041612 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 36
Study 15041612 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 36
Study 11346336 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.5 mg/m(2) per day
Number of subjects: 58
Study 11346336 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg/m(2) per day
Number of subjects: 58
Study 11346336 — intervention group
Group type: EXPERIMENTAL
Intervention: Above 300 mg/m(2) per day
Number of subjects: 58
Study 11346336 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover from 6.5 mg/m(2) per day to higher doses
Number of subjects: 58
Study 11346336 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-related adverse effects
Number of subjects: 58
Study 9006882 — intervention group
Group type: EXPERIMENTAL
Intervention: Local hand cooling (5‐7 degrees C)
Number of subjects: 10
Study 9006882 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined arterial occlusion and local cooling
Number of subjects: 10
Study 9006882 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial occlusion (3 min)
Number of subjects: 10
Study 8485071 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (5 mg, sublingual)
Number of subjects: 10
Study 8485071 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3688282 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylphenidate
Number of subjects: 2
Study 3688282 — intervention group
Group type: COMPARATOR
Intervention: Control (double-blind manner)
Number of subjects: 2
Study 29183035 — intervention group
Group type: EXPERIMENTAL
Intervention: RR with activated navigation system
Number of subjects: 42
Study 29183035 — intervention group
Group type: COMPARATOR
Intervention: RR without activated navigation system
Number of subjects: 42
Study 27218476 — intervention group
Group type: EXPERIMENTAL
Intervention: High concentration EtOH (targeted BrAC = 0.100 g/dl)
Number of subjects: 18
Study 27218476 — intervention group
Group type: EXPERIMENTAL
Intervention: Low concentration EtOH (targeted BrAC = 0.040 g/dl)
Number of subjects: 18
Study 27218476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 24274088 — intervention group
Group type: EXPERIMENTAL
Intervention: Death reminder
Number of subjects: 2
Study 24274088 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 2
Study 22619616 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mmHg pressure pneumoperitoneum
Number of subjects: 43
Study 22619616 — intervention group
Group type: COMPARATOR
Intervention: 14 mmHg pressure pneumoperitoneum
Number of subjects: 43
Study 20690561 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon and ribavirin treatment
Number of subjects: 78
Study 18444168 — intervention group
Group type: EXPERIMENTAL
Intervention: Lycopene supplementation (30 mg/day for 2 months)
Number of subjects: 60
Study 16006090 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron saccharate Venofer (5 mg/kg injection on day 1)
Number of subjects: 93
Study 16006090 — intervention group
Group type: COMPARATOR
Intervention: Control group without iron supplementation
Number of subjects: 93
Study 14644797 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraosseous access using Bone Injection Gun (BIG) while wearing protective gear
Number of subjects: 0
Study 14644797 — intervention group
Group type: COMPARATOR
Intervention: Intraosseous access using Bone Injection Gun (BIG) without protective gear
Number of subjects: 0
Study 11049243 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambroxol treatment (1,000 mg diluted in 500 ml of 5% glucose solution, given intravenously for 4 hours once a day for 3 days)
Number of subjects: 80
Study 11049243 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ambroxol administered)
Number of subjects: 80
Study 8795314 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-oxygenation (group 1)
Number of subjects: 27
Study 8795314 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxygenation (group 3)
Number of subjects: 27
Study 8795314 — intervention group
Group type: COMPARATOR
Intervention: No pre-oxygenation (group 2)
Number of subjects: 27
Study 1618668 — intervention group
Group type: EXPERIMENTAL
Intervention: EBIORT
Number of subjects: 37
Study 1618668 — intervention group
Group type: EXPERIMENTAL
Intervention: EBIORT plus ERT
Number of subjects: 37
Study 1618668 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 37
Study 6712466 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone sodium phosphate (6 mg/kg) over 48 hours
Number of subjects: 48
Study 6712466 — intervention group
Group type: COMPARATOR
Intervention: Control group (no steroids)
Number of subjects: 48
Study 30298202 — intervention group
Group type: EXPERIMENTAL
Intervention: tenofovir/emtricitabine + atazanavir/ritonavir (TDF/FTC + ATV/r)
Number of subjects: 293
Study 30298202 — intervention group
Group type: COMPARATOR
Intervention: abacavir/lamivudine + atazanavir (ABC/3TC + ATV)
Number of subjects: 293
Study 29947107 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise only (RES)
Number of subjects: 84
Study 29947107 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent aerobic and resistance exercise (CEX)
Number of subjects: 84
Study 29947107 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise only (AER)
Number of subjects: 84
Study 29947107 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise control (CON)
Number of subjects: 84
Study 27195809 — intervention group
Group type: EXPERIMENTAL
Intervention: IPV and the Workplace training
Number of subjects: 27
Study 27195809 — intervention group
Group type: COMPARATOR
Intervention: Control group (6 months delayed training)
Number of subjects: 27
Study 24324004 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute high altitude exposure (5050 m) in lowlanders
Number of subjects: 24
Study 24324004 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic high altitude exposure (days 12-14 at 5050 m) in lowlanders
Number of subjects: 24
Study 24324004 — intervention group
Group type: EXPERIMENTAL
Intervention: Highlanders at 5050 m
Number of subjects: 24
Study 24324004 — intervention group
Group type: COMPARATOR
Intervention: Normobaric hypoxic chamber exposure (F IO 2 = 0.11; 6 h) in lowlanders
Number of subjects: 24
Study 22827728 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineal massage during labor
Number of subjects: 396
Study 19894061 — intervention group
Group type: EXPERIMENTAL
Intervention: MYA during PEG
Number of subjects: 62
Study 19894061 — intervention group
Group type: EXPERIMENTAL
Intervention: MYA during STR
Number of subjects: 62
Study 19894061 — intervention group
Group type: COMPARATOR
Intervention: CON during PEG
Number of subjects: 62
Study 19894061 — intervention group
Group type: COMPARATOR
Intervention: CON during STR
Number of subjects: 62
Study 19894061 — intervention group
Group type: EXPERIMENTAL
Intervention: MYA vs CON (microdialysis)
Number of subjects: 62
Study 19894061 — intervention group
Group type: EXPERIMENTAL
Intervention: NIRS (both groups during PEG)
Number of subjects: 62
Study 19894061 — intervention group
Group type: EXPERIMENTAL
Intervention: VAS score at rest
Number of subjects: 62
Study 17011074 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish and English educational videos
Number of subjects: 107
Study 17011074 — intervention group
Group type: COMPARATOR
Intervention: Routine discussion
Number of subjects: 107
Study 16300166 — intervention group
Group type: EXPERIMENTAL
Intervention: EMD 87 580 (50 mg once daily) in patients with renal dysfunction (Group 2)
Number of subjects: 30
Study 16300166 — intervention group
Group type: COMPARATOR
Intervention: EMD 87 580 (100 mg twice daily) in patients with normal renal function (Group 1)
Number of subjects: 30
Study 16300166 — intervention group
Group type: EXPERIMENTAL
Intervention: EMD 87 580 (50 mg dose) in patients with renal dysfunction (Group 2)
Number of subjects: 30
Study 16300166 — intervention group
Group type: COMPARATOR
Intervention: EMD 87 580 (50 mg dose) in patients with normal renal function (Group 1)
Number of subjects: 30
Study 11883375 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% oxygen (oxygen group)
Number of subjects: 44
Study 11883375 — intervention group
Group type: COMPARATOR
Intervention: 21% oxygen (air group)
Number of subjects: 44
Study 9845636 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled group (32 patients, 40 anastomoses) with functional end-to-end anastomoses made with linear staplers and circular stapling anastomoses.
Number of subjects: 68
Study 9845636 — intervention group
Group type: COMPARATOR
Intervention: Hand-sewn group (36 patients, 48 anastomoses) with anastomoses achieved by layer-to-layer suturing.
Number of subjects: 68
Study 9845636 — intervention group
Group type: EXPERIMENTAL
Intervention: Both stapled and hand-sewn procedures.
Number of subjects: 68
Study 7877298 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversational recast language intervention
Number of subjects: 21
Study 7877298 — intervention group
Group type: COMPARATOR
Intervention: Imitative intervention
Number of subjects: 21
Study 2508850 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa (5-10 MU/m2 daily for 5 days, then 10 MU/m2 thrice weekly for 11 weeks)
Number of subjects: 71
Study 2508850 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 71
Study 47083 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal rabies vaccine
Number of subjects: 35
Study 47083 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular rabies vaccine
Number of subjects: 35
Study 31845191 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated micronutrients in support to the carbon cycle (Impryl, Parthenogen, Switzerland)
Number of subjects: 32
Study 31845191 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 32
Study 31287021 — intervention group
Group type: EXPERIMENTAL
Intervention: PPIUD intervention
Number of subjects: 39084
Study 28483015 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemocoagulase agkistrodon (2 U) injected 20 minutes before surgery and 4 and 24 hours after surgery
Number of subjects: 60
Study 28483015 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 60
Study 26260135 — intervention group
Group type: EXPERIMENTAL
Intervention: JOVEN/YOUTH: Juntos Opuestos a la Violence Entre Novios/Together Against Dating Violence
Number of subjects: 82
Study 26260135 — intervention group
Group type: COMPARATOR
Intervention: Control group (delayed condition)
Number of subjects: 82
Study 24107878 — intervention group
Group type: EXPERIMENTAL
Intervention: Valdoxan
Number of subjects: 0
Study 22137081 — intervention group
Group type: EXPERIMENTAL
Intervention: Resolute zotarolimus-DES (Medtronic CardioVascular)
Number of subjects: 2292
Study 22137081 — intervention group
Group type: COMPARATOR
Intervention: Xience everolimus-DES (Abbott Vascular)
Number of subjects: 2292
Study 22137081 — intervention group
Group type: EXPERIMENTAL
Intervention: Resolute zotarolimus-DES
Number of subjects: 2292
Study 22137081 — intervention group
Group type: COMPARATOR
Intervention: Xience everolimus-DES
Number of subjects: 2292
Study 19151284 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine
Number of subjects: 52
Study 19151284 — intervention group
Group type: COMPARATOR
Intervention: 4% lidocaine
Number of subjects: 52
Study 16838426 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (target dose 32 mg once daily, mean dose 24 mg)
Number of subjects: 7601
Study 16838426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7601
Study 16838426 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 7601
Study 15316867 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (5.0 mg)
Number of subjects: 170
Study 15316867 — intervention group
Group type: COMPARATOR
Intervention: Alfacalcidol (1 microg)
Number of subjects: 170
Study 11218056 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 0
Study 11218056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9481098 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% w/w DEC‐medicated salt
Number of subjects: 18
Study 9481098 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 18
Study 1555751 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholate (600 mg/day)
Number of subjects: 37
Study 1555751 — intervention group
Group type: COMPARATOR
Intervention: Untreated gallstone patients
Number of subjects: 37
Study 4006240 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (transdermal therapeutic system) for 4 weeks
Number of subjects: 37
Study 4006240 — intervention group
Group type: COMPARATOR
Intervention: Timolol (10-20 mg/d) for 6 weeks
Number of subjects: 37
Study 4006240 — intervention group
Group type: COMPARATOR
Intervention: Methyldopa (250-500 mg/d) for 6 weeks
Number of subjects: 37
Study 3312541 — intervention group
Group type: EXPERIMENTAL
Intervention: High-copper amalgam alloy
Number of subjects: 0
Study 3312541 — intervention group
Group type: COMPARATOR
Intervention: Conventional lathe-cut amalgam alloy
Number of subjects: 0
Study 30629782 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain-related images
Number of subjects: 55
Study 30629782 — intervention group
Group type: COMPARATOR
Intervention: Neutral images
Number of subjects: 55
Study 30629782 — intervention group
Group type: COMPARATOR
Intervention: Threatening information condition
Number of subjects: 55
Study 30629782 — intervention group
Group type: COMPARATOR
Intervention: Non-threatening information condition
Number of subjects: 55
Study 27771425 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 151
Study 27771425 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 151
Study 25381348 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral surgical nerve decompression at four sites in the lower extremity
Number of subjects: 39
Study 25381348 — intervention group
Group type: COMPARATOR
Intervention: Contralateral limb (control)
Number of subjects: 39
Study 24447017 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsive Teaching (RT)
Number of subjects: 15
Study 24447017 — intervention group
Group type: COMPARATOR
Intervention: Standard preschool classroom services
Number of subjects: 15
Study 22025606 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 2201
Study 22025606 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 2201
Study 18454659 — intervention group
Group type: EXPERIMENTAL
Intervention: HCP sheets combined with PRP and HA
Number of subjects: 30
Study 18454659 — intervention group
Group type: COMPARATOR
Intervention: PRP with HA
Number of subjects: 30
Study 16545251 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (3500 IU/d of bemiparin) subcutaneously for 6 months
Number of subjects: 87
Study 16545251 — intervention group
Group type: COMPARATOR
Intervention: Control group (no heparin prophylaxis)
Number of subjects: 87
Study 12694124 — intervention group
Group type: EXPERIMENTAL
Intervention: Menotreat
Number of subjects: 31
Study 12694124 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavaterm
Number of subjects: 31
Study 12694124 — intervention group
Group type: COMPARATOR
Intervention: Both methods
Number of subjects: 31
Study 10757566 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermic cardiopulmonary bypass (NTCPB) at 36-37 degrees C
Number of subjects: 36
Study 10757566 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermic cardiopulmonary bypass (HTCPB) at 28 degrees C
Number of subjects: 36
Study 10757566 — intervention group
Group type: COMPARATOR
Intervention: CABG patients without gross neurologic complications
Number of subjects: 36
Study 10757566 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG patients with neurologic complications
Number of subjects: 36
Study 8729673 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural rubber latex proteins
Number of subjects: 22
Study 8729673 — intervention group
Group type: EXPERIMENTAL
Intervention: Banana proteins
Number of subjects: 22
Study 8729673 — intervention group
Group type: EXPERIMENTAL
Intervention: Banana skin-prick test
Number of subjects: 22
Study 8729673 — intervention group
Group type: EXPERIMENTAL
Intervention: Banana RAST
Number of subjects: 22
Study 8729673 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoblotting
Number of subjects: 22
Study 8729673 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms from eating or handling bananas
Number of subjects: 22
Study 1384845 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% HES 200/0.6-0.66
Number of subjects: 12
Study 1384845 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer's solution
Number of subjects: 12
Study 2864158 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol
Number of subjects: 18
Study 2864158 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbimazole
Number of subjects: 18
Study 2864158 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 30577725 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand hygiene curriculum
Number of subjects: 95